BC Extra | Sep 27, 2017
Company News

Management tracks: Gilead, Tango, Rubius, Bicycle

Gilead Sciences Inc. (NASDAQ:GILD) said COO Kevin Young will retire, effective early 2018. Young returned to Gilead as COO in May 2016 after brief retirement during which he acted as an advisor. He was Gilead's...
BC Extra | Sep 8, 2017
Company News

Management tracks: Karolinska, Conatus, Theranexus

Life sciences investment company Karolinska Development AB (SSE:KDEV) named Fredrik Järrsten CFO effective "towards the end" of the year. He is CFO and business development director at Bactiguard Holding AB (SSE:BACTI-B). Liver disease play Conatus...
BC Extra | Aug 1, 2017
Company News

Management tracks: Bicycle, ReNetX, ALK-Abello

Peptide company Bicycle Therapeutics Ltd. (Cambridge, U.K.) named Lee Kalowski CFO. He was CFO of Tokai Pharmaceuticals Inc. , which merged with Otic Pharma Ltd. to form Novus Therapeutics Inc. (NASDAQ:NVUS). Neurology play ReNetX Bio (New...
BioCentury | Oct 3, 2016
Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
BC Extra | Sep 27, 2016
Company News

Management tracks

Antibody company Prothena Corp. plc (NASDAQ:PRTA) said President and CEO Dale Schenk is taking a medical leave of absence. He will remain on Prothena's board. COO Gene Kinney will lead the company in Schenk's absence....
BC Week In Review | Sep 5, 2016
Clinical News

Galeterone: Phase II discontinued

Tokai discontinued enrollment in the expansion portion of the open-label, international Phase II ARMOR2 trial of once-daily oral galeterone for 3 months in patients with acquired Xtandi enzalutamide resistance. The decision follows discontinuation of the...
BC Week In Review | Aug 15, 2016
Company News

Tokai cancer news

Tokai will reduce headcount by about 15 (60%) to 10 after it discontinued in July the Phase III ARMOR3-SV trial of galeterone ( TOK-001 ) to treat metastatic castration-resistant prostate cancer (CRPC). The biotech decided to discontinue...
BC Week In Review | Aug 1, 2016
Clinical News

Galeterone: Phase III discontinued

Tokai discontinued the open-label, international Phase III ARMOR3-SV trial in about 148 treatment-naive metastatic CRPC patients whose tumors express androgen receptor splice variant 7 (AR- V7 ) after an analysis by an IDMC showed that once-daily...
BC Extra | Jul 26, 2016
Clinical News

Tokai ending galeterone study

Tokai Pharmaceuticals Inc. (NASDAQ:TKAI) fell $4.10 (79%) to $1.10 on Tuesday after it said it would stop the Phase III ARMOR3-SV study of galeterone ( TOK-001 ) to treat metastatic castration-resistant prostate cancer (CRPC). Tokai said an...
BC Extra | Mar 24, 2016
Company News

Management tracks

Huya Bioscience International LLC (San Diego, Calif.), which is developing oncology and cardiovascular candidates sourced in China, named John Ratliff president and CEO. He replaces founder and CEO Mireille Gillings, who will continue as executive...
Items per page:
1 - 10 of 45
BC Extra | Sep 27, 2017
Company News

Management tracks: Gilead, Tango, Rubius, Bicycle

Gilead Sciences Inc. (NASDAQ:GILD) said COO Kevin Young will retire, effective early 2018. Young returned to Gilead as COO in May 2016 after brief retirement during which he acted as an advisor. He was Gilead's...
BC Extra | Sep 8, 2017
Company News

Management tracks: Karolinska, Conatus, Theranexus

Life sciences investment company Karolinska Development AB (SSE:KDEV) named Fredrik Järrsten CFO effective "towards the end" of the year. He is CFO and business development director at Bactiguard Holding AB (SSE:BACTI-B). Liver disease play Conatus...
BC Extra | Aug 1, 2017
Company News

Management tracks: Bicycle, ReNetX, ALK-Abello

Peptide company Bicycle Therapeutics Ltd. (Cambridge, U.K.) named Lee Kalowski CFO. He was CFO of Tokai Pharmaceuticals Inc. , which merged with Otic Pharma Ltd. to form Novus Therapeutics Inc. (NASDAQ:NVUS). Neurology play ReNetX Bio (New...
BioCentury | Oct 3, 2016
Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
BC Extra | Sep 27, 2016
Company News

Management tracks

Antibody company Prothena Corp. plc (NASDAQ:PRTA) said President and CEO Dale Schenk is taking a medical leave of absence. He will remain on Prothena's board. COO Gene Kinney will lead the company in Schenk's absence....
BC Week In Review | Sep 5, 2016
Clinical News

Galeterone: Phase II discontinued

Tokai discontinued enrollment in the expansion portion of the open-label, international Phase II ARMOR2 trial of once-daily oral galeterone for 3 months in patients with acquired Xtandi enzalutamide resistance. The decision follows discontinuation of the...
BC Week In Review | Aug 15, 2016
Company News

Tokai cancer news

Tokai will reduce headcount by about 15 (60%) to 10 after it discontinued in July the Phase III ARMOR3-SV trial of galeterone ( TOK-001 ) to treat metastatic castration-resistant prostate cancer (CRPC). The biotech decided to discontinue...
BC Week In Review | Aug 1, 2016
Clinical News

Galeterone: Phase III discontinued

Tokai discontinued the open-label, international Phase III ARMOR3-SV trial in about 148 treatment-naive metastatic CRPC patients whose tumors express androgen receptor splice variant 7 (AR- V7 ) after an analysis by an IDMC showed that once-daily...
BC Extra | Jul 26, 2016
Clinical News

Tokai ending galeterone study

Tokai Pharmaceuticals Inc. (NASDAQ:TKAI) fell $4.10 (79%) to $1.10 on Tuesday after it said it would stop the Phase III ARMOR3-SV study of galeterone ( TOK-001 ) to treat metastatic castration-resistant prostate cancer (CRPC). Tokai said an...
BC Extra | Mar 24, 2016
Company News

Management tracks

Huya Bioscience International LLC (San Diego, Calif.), which is developing oncology and cardiovascular candidates sourced in China, named John Ratliff president and CEO. He replaces founder and CEO Mireille Gillings, who will continue as executive...
Items per page:
1 - 10 of 45